FDA Approval of Olaparib for BRCA-Mutated Ovarian Cancer Treatment – 2014
Reading tools

Approved by the FDA on 19 December 2014, Lynparza began being used to treat women with advanced ovarian cancer carrying a BRCA gene mutation (genetic alteration).
Lynparza blocks the PARP enzyme, which repairs DNA damage. Besides the general side effects of most cancer drugs, caution is needed regarding development of Myelodysplastic Syndrome/Acute Myeloid Leukemia.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.